AL-2846 is under clinical development by Advenchen Laboratories and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AL-2846’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AL-2846 overview

AL-2846 is under development for the treatment of solid tumor, gastric cancer, breast cancer, renal cell carcinoma, advanced pancreatic cancer, colon cancer, advanced non-small cell lung cancer, breast cancer, prostate cancer, bladder cancer, medullary thyroid cancer, type I neurofibromatosis related neurofibromatosis and peripheral malignant nervous sheath tumor. It is formulated as a capsule and is administered through oral route. It acts by targeting c-Met receptor tyrosine kinase (RTK), Flt4 (VEGFR-3), KDR (VEGFR-2) and Ron.

 It was also under development for gastric cancer, renal cell carcinoma and breast cancer.

Advenchen Laboratories overview

Advenchen Laboratories is a pharmaceutical company that offers healthcare solutions. The company conducts pharmaceutical research and develops small molecule cancer drug discovery programs. It provides pipeline such as angiogenesis inhibitors and small molecule protein tyrosine kinases inhibitors, among others. Advenchen Laboratories provides services such as producing inhibitors for the treatment of human colon cancer, liver cancer, gastric cancer, lungs and breast cancer, among others. Advenchen Laboratories also provides customized chemical intermediate services. The company operates in China and the US. Advenchen Laboratories is headquartered in Moorpark, California, the US.

For a complete picture of AL-2846’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.